GKOS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

104.140

Open

102.780

VWAP

102.49

Vol

508.16K

Mkt Cap

5.97B

Low

100.465

Amount

52.08M

EV/EBITDA(TTM)

--

Total Shares

58.08M

EV

5.76B

EV/OCF(TTM)

--

P/S(TTM)

11.59

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Show More

Events Timeline

(ET)

2026-02-17

19:40:00

Investor Sentiment Uneasy as Major Indices Post Modest Gains

2026-02-17

16:10:00

Glaukos Q4 Revenue $143.1M Beats Expectations

2026-02-17

16:10:00

Glaukos Sees FY26 Revenue of $600M-$620M

2026-02-17

14:20:00

Notable Companies Reporting After Market Close

2026-01-28 (ET)

2026-01-28

07:30:00

Glaukos Receives FDA Approval for iDose TR Re-administration

News

Benzinga

Wingstop Reports Strong Q4 Earnings, Shares Surge

Benzinga

Glaukos Reports Mixed Q4 Results with Analyst Revisions

seekingalpha

02-18seekingalpha

Glaukos Corporation Reports Record Q4 2025 Earnings and Strong 2026 Guidance

seekingalpha

02-17seekingalpha

Glaukos Q4 Earnings Beat Expectations Despite EPS Miss

seekingalpha

02-15seekingalpha

Glaukos Set to Announce Q4 Earnings Expectations

NASDAQ.COM

01-31NASDAQ.COM

Glaukos Director Stapley Sells Shares Worth $1.9 Million

13 Analyst Rating

Wall Street analysts forecast GKOS stock price to rise

12 Buy

0 Hold

1 Sell

Strong Buy

Current: 0.000

Low

72.00

Averages

127.08

High

165.00

Current: 0.000

Low

72.00

Averages

127.08

High

165.00

Needham

David Saxon

Buy

maintain

$125 -> $127

AI Analysis

2026-02-18

Reason

Needham

David Saxon

Price Target

$125 -> $127

AI Analysis

2026-02-18

maintain

Buy

Reason

Needham analyst David Saxon raised the firm's price target on Glaukos to $127 from $125 and keeps a Buy rating on the shares after its Q4 revenue came in-line with its pre-announcement. iDose continues to ramp, with re-administration potentially starting to drive volume in the second half of this year, which should build into 2027 and beyond, the analyst tells investors in a research note.

Wells Fargo

Overweight

maintain

$122 -> $135

2026-02-18

Reason

Wells Fargo

Price Target

$122 -> $135

2026-02-18

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Glaukos to $135 from $122 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 sales in line with the January preannouncement and reiterated 2026 guidance. Wells believes management sees Epioxa volume ramping back to Photrexa peak by 2030, implying over $1B opportunity.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GKOS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Glaukos Corp (GKOS.N) is -198.99, compared to its 5-year average forward P/E of -64.26. For a more detailed relative valuation and DCF analysis to assess Glaukos Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-64.26

Current PE

-198.99

Overvalued PE

-16.59

Undervalued PE

-111.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-553.50

Current EV/EBITDA

-1373.43

Overvalued EV/EBITDA

2423.72

Undervalued EV/EBITDA

-3530.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

10.98

Current PS

11.13

Overvalued PS

14.23

Undervalued PS

7.73

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what can I invest to make fast cash

Intellectia · 102 candidates

Market Cap: 2.00B - 20.00BRsi Category: moderateRelative Vol: >= 1.20Beta: ModerateRisk, HighRiskWeek Price Change Pct: >= $3.00

Ticker

Name

Market Cap$

Glaukos Corp

7.13B

Bellring Brands Inc

3.33B

Photronics Inc

2.14B

Super Micro Computer Inc

19.25B

MYR Group Inc

3.99B

Gulfport Energy Corp

3.78B

best stocks to buy call options in now

Intellectia · 159 candidates

Rsi 14: 30 - 70Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00Is Optionable: TrueOption Sentiments: Bullish

Ticker

Name

Market Cap$

Illumina Inc

23.30B

Telefonica Brasil SA

20.77B

Galaxy Digital Inc

12.68B

Gildan Activewear Inc

12.27B

IAMGOLD Corp

11.42B

Millicom International Cellular SA

9.96B

Whales Holding GKOS

Sofinnova Investment, Inc.

Osterweis Capital Management, Inc.

Eversept Partners, L.P.

Granite Investment Partners, LLC

Bellevue Asset Management AG

Trading Trends

People Also Watch

Frequently Asked Questions

What is Glaukos Corp (GKOS) stock price today?

The current price of GKOS is 102.86 USD — it has decreased -0.28

What is Glaukos Corp (GKOS)'s business?

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

What is the price predicton of GKOS Stock?

Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Glaukos Corp (GKOS)'s revenue for the last quarter?

Glaukos Corp revenue for the last quarter amounts to 143.12M USD, increased 35.66

What is Glaukos Corp (GKOS)'s earnings per share (EPS) for the last quarter?

Glaukos Corp. EPS for the last quarter amounts to -2.32 USD, increased 286.67

How many employees does Glaukos Corp (GKOS). have?

Glaukos Corp (GKOS) has 1094 emplpoyees as of March 12 2026.

What is Glaukos Corp (GKOS) market cap?

Today GKOS has the market capitalization of 5.97B USD.